MorphoSys AG MPSYF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MPSYF is a good fit for your portfolio.
News
-
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
-
Trending: Novartis Begins Tender Offer for MorphoSys Shares
-
Novartis to bolster its cancer-drug portfolio with $2.9 billion deal for MorphoSys
-
MorphoSys Shares Jump After It Agrees to $2.9 Billion Takeover by Novartis
-
Novartis to Buy MorphoSys for $2.9 Billion; Deal Seen Closing in 1st Half
-
Novartis in Lead to Acquire Cancer-Drug Maker MorphoSys, Reuters Reports
-
MorphoSys Trial for Blood-Cancer Treatment Reaches Primary Endpoint
-
MorphoSys shares gain as endometrial cancer treatment gets fast-track designation
Trading Information
- Previous Close Price
- $71.76
- Day Range
- $73.27–73.27
- 52-Week Range
- $20.15–73.27
- Bid/Ask
- $70.66 / $78.96
- Market Cap
- $2.76 Bil
- Volume/Avg
- 3,700 / 6,402
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.75
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Value
- Total Number of Employees
- 464
- Website
- https://www.morphosys.com
Comparables
Valuation
|
Metric
|
MPSYF
|
02315
|
HPHA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 50.81 | 3.19 | 3.73 |
Price/Sales | 9.75 | 3.48 | 12.92 |
Price/Cash Flow | — | — | — |
Price/Earnings
MPSYF
02315
HPHA
Financial Strength
|
Metric
|
MPSYF
|
02315
|
HPHA
|
|---|---|---|---|
Quick Ratio | 3.14 | 0.96 | 4.85 |
Current Ratio | 3.57 | 1.25 | 6.13 |
Interest Coverage | — | −2.91 | −36.58 |
Quick Ratio
MPSYF
02315
HPHA
Profitability
|
Metric
|
MPSYF
|
02315
|
HPHA
|
|---|---|---|---|
Return on Assets (Normalized) | −14.65% | −13.53% | −16.41% |
Return on Equity (Normalized) | −384.47% | −37.28% | −29.22% |
Return on Invested Capital (Normalized) | −41.44% | −20.22% | −24.71% |
Return on Assets
MPSYF
02315
HPHA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Cbvgvhkdwj | Dtlm | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gyptywyzn | Zkyry | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dzpcqjf | Xtjrgr | $118.7 Bil | |||
| Moderna Inc
MRNA
| Wtnkrty | Mmps | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xdjslzxwc | Gctljk | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Lhrdrbk | Trww | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Ddyffgxw | Mbxh | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Chbtlrl | Zxhrvz | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Bvjqtmjm | Lgjzd | $15.0 Bil | |||
| Incyte Corp
INCY
| Zmjpfhyc | Szythcq | $13.5 Bil |